logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Geely Auto (00175) issued 7500 shares due to the exercise of stock options.

date
23/06/2025
avatar
GMT Eight
Geely Automobile (00175) announced that on June 23, 2025, it will issue stock options to group employees according to the stock option plan.
Geely Auto (00175) announced that on June 23, 2025, 7500 shares were issued due to the exercise of stock options by employees under the stock option plan adopted on April 28, 2023.
Related Articles
HK Stock
Modern Dental (03600) repurchased 100,000 shares at a cost of HK$412,500 on June 23rd.
HK Stock
YAN PALACE (01497) plans to repurchase up to 46.55 million H shares.
China Stock
Sichuan Biokin Pharmaceutical (688506.SH): The first patient has been enrolled in the Phase III clinical trial evaluating the postoperative adjuvant therapy of HER2 ADC for HER2-positive breast cancer with residual invasive cancer after neoadjuvant treatment.
Modern Dental (03600) repurchased 100,000 shares at a cost of HK$412,500 on June 23rd.
HK Stock
YAN PALACE (01497) plans to repurchase up to 46.55 million H shares.
HK Stock
Sichuan Biokin Pharmaceutical (688506.SH): The first patient has been enrolled in the Phase III clinical trial evaluating the postoperative adjuvant therapy of HER2 ADC for HER2-positive breast cancer with residual invasive cancer after neoadjuvant treatment.
China Stock
RECOMMEND
XPeng Motors Faces Whistleblower Allegations Over Steering Design Flaw and Concealment
XPeng Motors Faces Whistleblower Allegations Over Steering Design Flaw and Concealment
icon
20/06/2025
After Foundation Models, Intelligent Agents Take Center Stage as Tech Firms Accelerate Deployment | Live from MWC Shanghai
After Foundation Models, Intelligent Agents Take Center Stage as Tech Firms Accelerate Deployment | Live from MWC Shanghai
icon
20/06/2025
Ministry of Commerce: Online Retail Sales Increased by 8.5% from January to May
Ministry of Commerce: Online Retail Sales Increased by 8.5% from January to May
icon
20/06/2025
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.